Wechselwirkungen · Prezista
PREZISTA 400 mg film-coated tablets PREZISTA 800 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 93
HOS-116602 · Präparat HOS-094447
INTERACTIONS AND DOSE RECOMMENDATIONS WITH OTHER MEDICINAL PRODUCTS Medicinal product Interaction Recommendations concerning examples by therapeutic Geometric mean change (%) co-administration area HIV ANTIRETROVIRALS Integrase strand transfer inhibitors Dolutegravir dolutegravir AUC ↓ 22% Boosted PREZISTA and dolutegravir C24h ↓ 38% dolutegravir can be used without dolutegravir Cmax ↓ 11% dose adjustment. darunavir ↔* * Using cross-study comparisons to historical pharmacokinetic data Raltegravir Some clinical studies suggest raltegravir At present the effect of raltegravir may cause a modest decrease in on darunavir plasma darunavir plasma concentrations. concentrations does not appear to be clinically relevant. Boosted PREZISTA and raltegravir can be used without dose adjustments. Nucleo(s/t)ide reverse transcriptase inhibitors (NRTIs) Didanosine didanosine AUC ↓ 9% Boosted PREZISTA and 400 mg once daily didanosine Cmin ND didanosine can be used without didanosine Cmax ↓ 16% dose adjustments. darunavir AUC ↔ Didanosine is to be administered darunavir Cmin ↔ on an empty stomach, thus it darunavir Cmax ↔ should be administered 1 hour before or 2 hours after boosted PREZISTA given with food.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): dolutegravir (HOS-089992) didanosine (HOS-085836) raltegravir (HOS-086187)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 585aa838af78d412bb92c3071362c4c9c0001259848f355bfd7dbaf40f91a7bf · Zeichen 7993–10312 im Abschnitt